Published in PLoS Pathog on January 01, 2007
Ebola haemorrhagic fever. Lancet (2011) 8.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A (2012) 3.35
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A (2012) 2.83
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep (2013) 2.01
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Ebolavirus glycoprotein structure and mechanism of entry. Future Virol (2009) 1.56
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A (2014) 1.44
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog (2010) 1.29
Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol (2009) 1.28
Structural basis for differential neutralization of ebolaviruses. Viruses (2012) 1.15
Virological and serological findings in Rousettus aegyptiacus experimentally inoculated with vero cells-adapted hogan strain of Marburg virus. PLoS One (2012) 1.15
Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. J Mol Biol (2007) 1.14
Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci Rep (2016) 1.13
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology (2010) 1.09
Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One (2014) 1.08
Mouse models for filovirus infections. Viruses (2012) 1.07
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04
Antibodies for biodefense. MAbs (2011) 1.02
An update on the use of antibodies against the filoviruses. Immunotherapy (2013) 1.01
Ebolavirus vaccines for humans and apes. Curr Opin Virol (2012) 1.01
Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis (2011) 0.99
Antibodies against viruses: passive and active immunization. Curr Opin Immunol (2008) 0.97
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science (2016) 0.97
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Discovery of an antibody for pan-ebolavirus therapy. Sci Rep (2016) 0.93
Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev (2015) 0.92
Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science (2016) 0.92
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J Virol (2014) 0.91
State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. J Infect Dis (2015) 0.90
Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infect Dis (2014) 0.87
Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother (2015) 0.86
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One (2012) 0.85
Antibody therapy for Ebola: is the tide turning around? Hum Vaccin Immunother (2014) 0.84
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PLoS One (2015) 0.83
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Rep (2016) 0.83
Ebola virus entry into host cells: identifying therapeutic strategies. Curr Clin Microbiol Rep (2015) 0.82
Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology (2014) 0.82
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One (2013) 0.81
Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virol J (2009) 0.79
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Antibody therapeutics for Ebola virus disease. Curr Opin Virol (2016) 0.78
Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol (2016) 0.78
Evasion of the interferon-mediated antiviral response by filoviruses. Viruses (2010) 0.77
Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. EBioMedicine (2015) 0.77
Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol (2017) 0.77
Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep (2016) 0.77
Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Sci Rep (2016) 0.76
Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs. PLoS One (2016) 0.76
IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. MAbs (2017) 0.76
Cell-targeting antibodies in immunity to Ebola. Pathog Dis (2016) 0.75
Initiating a watch list for Ebola virus antibody escape mutations. PeerJ (2016) 0.75
Therapeutics for postexposure treatment of Ebola virus infection. Future Virol (2015) 0.75
Stability of isolated antibody-antigen complexes as a predictive tool for selecting toxin neutralizing antibodies. MAbs (2016) 0.75
Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep (2017) 0.75
Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Sci Rep (2016) 0.75
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep (2017) 0.75
In silico prediction of Ebola Zaire GP(1,2) immuno-dominant epitopes for the Balb/c mouse. BMC Immunol (2015) 0.75
Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus (2015) 0.75
Ebola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent Updates. J Clin Diagn Res (2015) 0.75
Containing the contagion: treating the virus that inspired the film. Sci Transl Med (2011) 0.75
Traditional passive immune therapy for emerging Ebola infection. Emerg Microbes Infect (2014) 0.75
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 4.92
Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 4.18
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 3.62
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47
Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol (2006) 3.04
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis (1980) 2.38
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis (1995) 1.86
Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis (1999) 1.83
An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis (1999) 1.67
Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol (2006) 1.47
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44
Viral piracy: HIV-1 targets dendritic cells for transmission. Curr HIV Res (2006) 1.35
Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol (1999) 1.31
Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med (1998) 1.29
Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis (1998) 1.23
[Development and study of the properties of immunoglobulin against Ebola fever]. Vopr Virusol (1996) 1.19
[Developing principles for emergency prevention and treatment of Ebola fever]. Vopr Virusol (1997) 1.03
Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology (2002) 0.90
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Ebola haemorrhagic fever. Lancet (2011) 8.28
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Toward an AIDS vaccine. Science (2008) 4.83
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
HIV vaccine research: the way forward. Science (2008) 3.86
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 3.59
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62